12:00 AM
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK2248761: FDA hold

Idenix said FDA placed a clinical hold on GSK2248761 after 4 patients experienced seizures during the Phase IIb SONNET trial in treatment-experienced patients. GlaxoSmithKline said that the patients have recovered and that it will investigate...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >